Intravital imaging to monitor therapeutic response in moving hypoxic regions resistant to PI3K pathway targeting in pancreatic cancer

Conway, J. R.W. et al. (2018) Intravital imaging to monitor therapeutic response in moving hypoxic regions resistant to PI3K pathway targeting in pancreatic cancer. Cell Reports, 23(11), pp. 3312-3326. (doi:10.1016/j.celrep.2018.05.038) (PMID:29898401) (PMCID:PMC6019737)

[img]
Preview
Text
164423.pdf - Published Version
Available under License Creative Commons Attribution.

10MB

Abstract

Application of advanced intravital imaging facilitates dynamic monitoring of pathway activity upon therapeutic inhibition. Here, we assess resistance to therapeutic inhibition of the PI3K pathway within the hypoxic microenvironment of pancreatic ductal adenocarcinoma (PDAC) and identify a phenomenon whereby pronounced hypoxia-induced resistance is observed for three clinically relevant inhibitors. To address this clinical problem, we have mapped tumor hypoxia by both immunofluorescence and phosphorescence lifetime imaging of oxygen-sensitive nanoparticles and demonstrate that these hypoxic regions move transiently around the tumor. To overlay this microenvironmental information with drug response, we applied a FRET biosensor for Akt activity, which is a key effector of the PI3K pathway. Performing dual intravital imaging of drug response in different tumor compartments, we demonstrate an improved drug response to a combination therapy using the dual mTORC1/2 inhibitor AZD2014 with the hypoxia-activated pro-drug TH-302.

Item Type:Articles
Additional Information:This work was supported by an NHMRC Project Grant, an NHMRC Fellowship, an NBCF Innovator Grant, an ARC Future Fellowship, a Len Ainsworth Pancreatic Cancer Fellowship, Cancer Council NSW Grant, a Tour de Cure Grant, and CRUK core funding (A17196 and A21139). This project was made possible by an Avner Pancreatic Cancer Foundation Grant.
Keywords:AZD2014, Akt, FRET, PI3K pathway, PLIM, hypoxia, intravital imaging, nanoparticles, pancreatic cancer, pro-drug.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Morton, Dr Jennifer and Timpson, Dr Paul and Sansom, Professor Owen
Authors: Conway, J. R.W., Warren, S. C., Herrmann, D., Murphy, K. J., Cazet, A. S., Vennin, C., Shearer, R. F., Killen, M. J., Magenau, A., Mélénec, P., Pinese, M., Nobis, M., Zaratzian, A., Boulghourjian, A., Da Silva, A. M., Del Monte-Nieto, G., Adam, A. S.A., Harvey, R. P., Haigh, J. J., Wang, Y., Croucher, D. R., Sansom, O. J., Pajic, M., Caldon, C. E., Morton, J. P., and Timpson, P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Cell Reports
Publisher:Elsevier (Cell Press)
ISSN:2211-1247
ISSN (Online):2211-1247
Published Online:13 June 2018
Copyright Holders:Copyright © 2018 Crown Copyright
First Published:First published in Cell Reports 23(11): 3312-3326
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record